Pulse Biosciences (NASDAQ:PLSE) Stock Price Up 6.9%

Pulse Biosciences, Inc. (NASDAQ:PLSEGet Free Report)’s share price rose 6.9% during trading on Wednesday . The stock traded as high as $9.80 and last traded at $9.80. Approximately 9,760 shares were traded during trading, a decline of 95% from the average daily volume of 185,756 shares. The stock had previously closed at $9.17.

Wall Street Analysts Forecast Growth

Separately, StockNews.com upgraded Pulse Biosciences to a “sell” rating in a report on Monday, November 20th.

View Our Latest Stock Report on Pulse Biosciences

Pulse Biosciences Trading Up 1.6 %

The firm has a fifty day moving average of $9.18 and a two-hundred day moving average of $7.31.

Insiders Place Their Bets

In other Pulse Biosciences news, Director Robert W. Duggan acquired 90,118 shares of the company’s stock in a transaction on Monday, December 11th. The stock was acquired at an average price of $9.36 per share, for a total transaction of $843,504.48. Following the acquisition, the director now owns 36,966,180 shares in the company, valued at approximately $346,003,444.80. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Company insiders own 69.70% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently added to or reduced their stakes in the stock. LM Advisors LLC purchased a new position in Pulse Biosciences during the fourth quarter valued at $30,000. Osaic Holdings Inc. raised its stake in shares of Pulse Biosciences by 4.7% in the second quarter. Osaic Holdings Inc. now owns 58,982 shares of the company’s stock worth $424,000 after purchasing an additional 2,672 shares during the last quarter. Geode Capital Management LLC raised its stake in shares of Pulse Biosciences by 2.1% in the first quarter. Geode Capital Management LLC now owns 142,490 shares of the company’s stock worth $479,000 after purchasing an additional 2,933 shares during the last quarter. Nuveen Asset Management LLC raised its stake in shares of Pulse Biosciences by 15.8% in the fourth quarter. Nuveen Asset Management LLC now owns 26,372 shares of the company’s stock worth $323,000 after purchasing an additional 3,607 shares during the last quarter. Finally, BNP Paribas Arbitrage SNC raised its stake in shares of Pulse Biosciences by 713.8% in the second quarter. BNP Paribas Arbitrage SNC now owns 4,199 shares of the company’s stock worth $30,000 after purchasing an additional 3,683 shares during the last quarter. Hedge funds and other institutional investors own 6.62% of the company’s stock.

Pulse Biosciences Company Profile

(Get Free Report)

Pulse Biosciences, Inc operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology.

Further Reading

Receive News & Ratings for Pulse Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulse Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.